Dendreon Corporation (NASDAQ: DNDN) is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization, and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering, and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010 and by the European Medicines Agency in 2013. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and has manufacturing facilities in Georgia and California.

PAVING A NEW PATH FOR TREATING CANCER

PROVENGE® (sipuleucel-T) is the first autologous cellular immunotherapy to receive FDA approval for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. PROVENGE is designed to take the body’s own immune cells and reprogram them to attack advanced prostate cancer.

CLINICAL TRIALS

Dendreon has several ongoing clinical trials, including:

Sipuleucel-T Clinical Trials

P10-1

An Open-Label, Multicenter Study of Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer Patients Previously Treated with Sipuleucel-T on Dendreon Study P-11 To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P10-2

A Randomized, Open-Label, Phase 2 Trial Examining the Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Non-Metastatic Prostate Cancer and a Rising Prostate Specific Antigen After Primary Therapy. To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P10-3 (called PROCEED)

A Registry of Sipuleucel-T in Men with Advanced Prostate Cancer (called PROCEED) to Further Evaluate Safety and Survival Associated with Sipuleucel-T To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

P11-1

An Open-Label Study of Sipuleucel-T in European Men with Metastatic, Castrate Resistant Prostate Cancer To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P11-3

A Randomized, Open-Label, Phase 2 Trial of Sipuleucel-T with Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men with Metastatic Castrate Resistant Prostate Cancer To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P11-4 (PRIME)

Immune Monitoring Protocol in Men with Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P12-1

An Observational Study to Evaluate Characteristics Predictive of a Positive Imaging Study for Metastatic Disease in Castrate-Resistant Prostate Cancer To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

P12-2

A Randomized, Open-Label, Phase 2 Trial Examining Combination Therapy with Sipuleucel-T and Enzalutamide in Men with Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer. To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov

Additional ACI Product Candidate Clinical Trials

N10-1 (called Neu-ACT)

A Randomized, Phase 2, Open-Label Study Evaluating DN24-02 as Adjuvant Therapy in Subjects with High Risk HER2+ Urothelial Carcinoma To learn more about the eligibility criteria and to find a clinical research facility nearest you, please click here or go to http://www.clinicaltrials.gov.

PATIENT INFORMATION

To find out more about cancer and specifically prostate cancer, we have provided a list of patient-focused cancer organizations.

Investor Relations

Stock Quote (NASDAQ: DNDN)

Price:

2.04

Change:

+ 0.03

Volume:

1,783,600

4:00 PM ET on Jun 13, 2014

Delayed at least 20 minutes. Provided by eSignal.

3 Mo. 6 Mo. 1 Yr.

Dendreon Corporation is a biotechnology company focused on targeting cancer and transforming lives through the discovery, development and commercialization of novel therapeutics that may significantly improve cancer treatment options for patients.